TY - JOUR
T1 - Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
AU - Farber, Harrison W.
AU - Miller, Dave P.
AU - McGoon, Michael D.
AU - Frost, Adaani E.
AU - Benton, Wade W.
AU - Benza, Raymond L.
N1 - Funding Information:
Harrison W. Farber, MD, serves as a consultant and is on the speaker’s bureau for Actelion, Ikaria, BMS, Bayer, United Therapeutics, and Gilead, receives grant/research support from Gilead and United Therapeutics, and has received honoraria for his service on the REVEAL Registry Steering Committee, which is supported by Actelion Pharmaceuticals US Inc on behalf of Cotherix Inc. Dave P. Miller, MS, is an employee of ICON Clinical Research, the biostatistics CRO for the REVEAL Registry. Michael D. McGoon, MD, has served as the primary investigator for grants received by his institution from Gilead Sciences Inc and Medtronic Inc, has served on advisory, steering, and/or end point/Data and Safety Monitoring Board committees for Actelion Pharmaceuticals US Inc, Gilead Sciences Inc, Lung LLC, and GlaxoSmithKline, has received honoraria for speaking at conferences supported by Actelion Pharmaceuticals US Inc and Gilead Sciences Inc, and has received honoraria for his service on the REVEAL Registry Steering Committee, which is supported by Actelion Pharmaceuticals US Inc on behalf of Cotherix Inc. Adaani E. Frost, MD, has received honoraria for service on steering committees or advisory boards (or as a consultant) to the following companies working in the area of pulmonary hypertension: Actelion/CoTherix, Gilead, Pfizer, United Therapeutics/Lung Rx, GlaxoSmithKline, Lilly/ICOS, Bayer, Ikaria, and Arena, has received grant support for clinical studies from Ventripoint, GlaxoSmithKline, Actelion, Gilead, Pfizer, United Therapeutics/Lung Rx, Intermune, Stomedix, Bayer, and Novartis, and has received honoraria for her service on the REVEAL Registry Steering Committee, which is supported by Actelion Pharmaceuticals US Inc on behalf of Cotherix Inc. Wade W. Benton, PharmD, is an employee of Actelion Pharmaceuticals US Inc. Raymond L. Benza, MD, has received grant support from United Therapeutics, Gilead, Ikaria, and GeNo, and has received honoraria for his service on the REVEAL Registry Steering Committee, which is supported by Actelion Pharmaceuticals US, Inc. on behalf of Cotherix Inc.
Publisher Copyright:
© 2015 International Society for Heart and Lung Transplantation. All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background Clinical studies of pulmonary arterial hypertension have used the change in the 6-minute walk distance (6MWD) as a clinical end point; however, its association with survival outcomes has not been well established. In this analysis, we examined the prognostic value of the baseline 6MWD, absolute thresholds of the 6MWD, and change in the 6MWD. Methods Patients in the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) with 6MWD at enrollment, with or without a follow-up assessment within the first year of observation, were included. Kaplan-Meier survival estimates were computed for sub-sets with baseline 6MWD results that were above or below all possible thresholds and for sub-sets with a change in the 6MWD that was 10 percentage points above or below all possible thresholds, including improvement thresholds and worsening thresholds. Multivariable Cox regression models assessed the effect of improvement and worsening in the 6MWD on 1-year survival, adjusted for baseline factors. Results One-year survival estimates were higher for patients with a baseline 6MWD above vs below a threshold, although no specific threshold was more prognostic than another. In a model adjusted for the baseline 6MWD and risk score, worsening of the 6MWD over time significantly predicted decreased survival, but improvement in the 6MWD did not affect survival. Conclusions No 6MWD improvement threshold carries particular prognostic value. Improvement in the 6MWD was not associated with survival, but worsening of the 6MWD was strongly and significantly associated with poor prognosis.
AB - Background Clinical studies of pulmonary arterial hypertension have used the change in the 6-minute walk distance (6MWD) as a clinical end point; however, its association with survival outcomes has not been well established. In this analysis, we examined the prognostic value of the baseline 6MWD, absolute thresholds of the 6MWD, and change in the 6MWD. Methods Patients in the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) with 6MWD at enrollment, with or without a follow-up assessment within the first year of observation, were included. Kaplan-Meier survival estimates were computed for sub-sets with baseline 6MWD results that were above or below all possible thresholds and for sub-sets with a change in the 6MWD that was 10 percentage points above or below all possible thresholds, including improvement thresholds and worsening thresholds. Multivariable Cox regression models assessed the effect of improvement and worsening in the 6MWD on 1-year survival, adjusted for baseline factors. Results One-year survival estimates were higher for patients with a baseline 6MWD above vs below a threshold, although no specific threshold was more prognostic than another. In a model adjusted for the baseline 6MWD and risk score, worsening of the 6MWD over time significantly predicted decreased survival, but improvement in the 6MWD did not affect survival. Conclusions No 6MWD improvement threshold carries particular prognostic value. Improvement in the 6MWD was not associated with survival, but worsening of the 6MWD was strongly and significantly associated with poor prognosis.
KW - 6-minute walk distance
KW - prognostic value
KW - pulmonary arterial hypertension
KW - surrogate end points
KW - survival outcomes
UR - http://www.scopus.com/inward/record.url?scp=84925296872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925296872&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2014.08.020
DO - 10.1016/j.healun.2014.08.020
M3 - Article
C2 - 25312386
AN - SCOPUS:84925296872
SN - 1053-2498
VL - 34
SP - 362
EP - 368
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 3
ER -